Supporting Data Release Notes – 4.61

February 6, 2025

# Overview

This release notes document provides a high-level list of changes. More specific details can be found inside supporting data spreadsheets in the Change History tab.

# Structural Changes

* n/a

# Schedule Supporting Data Changes

Table 1: Schedule Supporting Data Changes

|  |  |
| --- | --- |
| **Supporting Data** | **Change** |
| Coded Observations | * New coded observations to support Chikungunya indications and contraindications. * New coded observations to support Hib indications. * Added Contraindication text description to observation 186. |
| CVX to Antigen | * Added new Chikungunya vaccine (CVX 317). |
| Vaccine Group | * Added new Chikungunya vaccine group. |
| Vaccine Group to Antigen | * Added new Chikungunya vaccine group. |

# Antigen Series Supporting Data Changes

Table 2: Antigen Series Specific Supporting Data Changes

|  |  |
| --- | --- |
| **Supporting Data** | **Change** |
| Chikungunya | * Newly created antigen supporting data file. |
| COVID-19 | * Removed unnecessary age values on age-based and risk-based pediatric series (Pfizer, Moderna, and mixed product). * Moved CVX 230 on dose 1 of the Start at 5 years+ series from an Allowable Vaccine to an Inadvertent Vaccine. |
| Hepatitis B | * Removed pregnancy contraindication for Heplisav-B (CVX 89). * Added new administrative guidance for HepB product usage in pregnant persons * Removed Prehevbrio (CVX 220) as a preferable vaccine across all series and all doses as Prehevbrio has been discontinued. |
| Hib | * Added 2 new indications to the risk child 2-dose series. |
| Influenza | * Corrected the volume on CVX 135 from 0.7 mL to 0.5 mL. * Added administrative guidance for off-label usage allowance of HD-IIV3 and aIIV3 in specific populations. * Removed three legacy administrative guidance statements to reduce the overall number of administrative guidance statements. |
| Measles | * Added MMRV-specific contraindication (HIV infection). |
| Meningococcal B | * Added administrative guidance to delay vaccination until after pregnancy due to lack of safety data. * Added a skip condition to dose 2 and dose 3 of the Bexsero risk series to address 2-dose administration patterns under previous licensure and new clinical guidance for the 3-dose licensure. |
| Mumps | * Added MMRV-specific contraindication (HIV infection). |
| Pneumococcal | * Added administrative guidance to support the use of PCV15 or PCV20 in adults when PPSV23 is unavailable. * Adjusted (added/removed/updated) preferable vaccines in 19+ risk-based series to align with the latest adult timing job aid:  <https://www.cdc.gov/pneumococcal/downloads/Vaccine-Timing-Adults-JobAid.pdf> * Created a PCV13-specific series for those 50 years and older to address dose 2 recommendations which vary from persons who received PCV15. |
| Polio | * Added missing allowable vaccine to 5-dose series. |
| Rubella | * Added MMRV-specific contraindication (HIV infection). |
| Varicella | * Added MMRV-specific contraindication (HIV infection). |